Treatment of diffuse large-cell lymphoma with anti-CD20 antibody
The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen.
1. A method of treating a >60 year old diffuse large cell lymphoma patient comprising administering anti-CD20 antibody and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the anti-CD20 antibody is administered to the patient in combination with a transplantation regimen.
2. The method of claim 1 , wherein the antibody comprises a chimeric anti-CD20 antibody.
3. The method of claim 2 , wherein the antibody comprises rituximab.
4. The method of claim 1 , wherein the lymphoma is accompanied by bone marrow involvement.
5. The method of claim 1 , wherein the transplantation regimen comprises bone marrow transplantation.
6. The method of claim 1 , wherein the anti-CD20 antibody and CHOP are administered simultaneously.
7. The method of claim 6 , wherein the anti-CD20 antibody and CHOP are administered concurrently.
8. The method of claim 7 , wherein the antibody comprises rituximab.
9. The method of claim 6 , comprising administering the anti-CD20 antibody on Day 1 of each chemotherapy cycle and the CHOP on Day 1 of each chemotherapy cycle.
10. The method of claim 9 , wherein the antibody comprises rituximab.
11. A method of treating a patient with diffuse large cell lymphoma comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the patient is >60 years old and wherein the rituximab and the CHOP are administered concurrently.
12. A method of treating a >60 year old diffuse large cell lymphoma patient comprising administering rituximab and CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) chemotherapy to the patient, wherein the rituximab is administered on Day 1 of each chemotherapy cycle and the CHOP is administered on Day 1 of each chemotherapy cycle.
13. The method of claim 9 comprising administering six or eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m 2 dose of the anti-CD20 antibody is administered to the patient.
14. The method of claim 13 comprising administering eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m 2 dose of the anti-CD20 antibody is administered to the patient.
15. The method of claim 12 comprising administering six or eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m 2 dose of rituximab is administered to the patient.
16. The method of claim 15 comprising administering eight chemotherapy cycles, wherein in each chemotherapy cycle a 375 mg/m 2 dose of rituximab is administered to the patient.